0IDA.L

Dynavax Technologies Corporation [0IDA.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0IDA.L Stock Summary

Top 10 Correlated ETFs

0IDA.L

Top 10 Correlated Stocks

0IDA.L

In the News

0IDA.L Financial details

Company Rating
-
Market Cap
1.54B
Income
-6.39M
Revenue
232.28M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
408
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
32.53
Forward P/E
-
PEG
-3.18
P/S
5.02
P/B
3.29
P/C
-
P/FCF
15.41
Quick Ratio
14.16
Current Ratio
15.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.05
EPS next Y
-
EPS next Q
-
EPS this Y
-102.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-52.81%
Revenue last 5Y
45.83%
Revenue Q/Q
-20.02%
EPS Q/Q
-98.45%
-
-
-
-
SMA20
-20.13%
SMA50
-14.92%
SMA100
-11.12%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
11%
ROC
0.08%
Gross Margin
65%
Oper. Margin
21%
Profit Margin
17%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.498-15.15
52W High
-22.67%
52W Low
+28.89%
RSI
45.88
Rel Volume
-
Avg Volume
1.12K
Volume
1
Perf Week
10.37%
Perf Month
-16.61%
Perf Quarter
-0.68%
Perf Half Y
3.57%
-
-
-
-
Beta
1.282
-
-
Volatility
0.29%, 1.23%
Prev Close
2.93%
Price
11.6
Change
2.93%

Something similar

Top by Market Cap
VTSAX
DHR-PB
NVDA
AAPL
GOOG
Top Correlated ETFs
DRGN.MI
HSUN
BLCK.TO
PHR.TO
ETP.TO
Top Correlated Stocks
TCPLPACK.NS
8203.HK
2863.HK
FRX.TO
ASHIANA.NS
Similar Market Cap
0032.HK
002825.SZ
600128.SS
KSB3.DE
002862.SZ

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 1.12K
  • Market Capitalization 1.54B
  • Employee 408
  • CEO Mr. David F. Novack
  • Headquarters EmeryVille,CA,US
  • IPO Date 2018-01-29
  • Website https://www.dynavax.com

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.